Palo Alto – September 26, 2017 – Cooley advised Lightstone Ventures on the closing of Lightstone Ventures II (LSV II), an over-subscribed fund that exceeded its $200 million target with $250 million in capital commitments. With LSV II, Lightstone will continue to focus on early-stage therapeutic opportunities across the life sciences sector.
“The successful implementation of our strategy requires the ability to identify, access and build upon key scientific discoveries. In less than five years, we’ve established a global footprint with unique initiatives underway in the US, Europe and Asia,” said Mike Carusi, general partner at Lightstone. “The strong interest we received in this fund from both new and existing limited partners represents a vote of confidence in our strategy, our team and our continued success. We would like to thank them for their support.”
Lightstone’s overarching goal is to fund companies developing therapies that have the potential to change the practice of medicine. In addition, Lightstone will also continue its company creation efforts. This includes continued collaboration with The Foundry, a leading medical device incubator, as well as other corporate, academic and strategic partners.
Lightstone, founded in 2012 by the general partners and other key members of the life science teams of Advanced Technology Ventures and Morgenthaler, invests in early-stage breakthrough medical device and biopharmaceutical companies.
Cooley VC partners Craig Dauchy and Nicole Peppe led the team advising Lightstone.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.